Need professional-grade analysis? Visit stockanalysis.com
$6.97B
N/A
67
N/A
Price Chart
Risk-Adjusted Performance
Abivax SA (ABVX) Price Performance
Abivax SA (ABVX) trades on Euronext Paris in EUR. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at EUR109.40, up 1.86% from the previous close.
Over the past year, ABVX has traded between a low of EUR4.56 and a high of EUR122.40. The stock has gained 1530.4% over this period. It is currently 10.6% below its 52-week high.
Abivax SA has a market capitalization of $6.97B.
About Abivax SA
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Company Info
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- Euronext Paris
- Currency
- EUR
- Country
- France
Financial Metrics
- Revenue (TTM)
- $6.02M
- EBITDA
- $-185,652,000
- Profit Margin
- -1633.08%
- EPS (TTM)
- -3.09
- Book Value
- -0.76
Technical Indicators
- 52 Week High
- €132.00
- 52 Week Low
- €4.51
- 50 Day MA
- €77.87
- 200 Day MA
- €32.82
- Beta
- -0.11
Valuation
- Trailing P/E
- N/A
- Forward P/E
- N/A
- Price/Sales
- 1527.56
- Price/Book
- 15.87
- Enterprise Value
- $7.57B